Type 2 diabetes (T2D) is a potential risk factor for poor outcomes associated with COVID-19, as are associated conditions including obesity, chronic kidney disease, and socioeconomic risk factors. T2D providers during the pandemic are thus caring for an especially vulnerable population. Published literature as well as online media, including patient discussion forums, raise questions about T2D management during the pandemic. For example, does glycemic control mitigate COVID-19 risk? Do specific diabetes drugs confer benefit or risk in the setting of SARS-CoV-2 exposure?
